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Abstract. Objective: The aim of this study was to establish the diagnostic performance of two biological 
markers - fatty liver index (FLI) and SteatoTest, in identifying hepatic steatosis and assessing its degree. 
Material  and  Methods:  Seventy  seven  patients  with  biopsy-proven  non-alcoholic  fatty  liver  disease 
(NAFLD) were prospectively studied and compared with 18 healthy subjects. The patients were stratified 
according  to  the  degree  of  hepatic  steatosis.  Two  biochemical  markers,  FLI  and  SteatoTest,  were 
determined. The diagnostic value of each method was assessed using sensitivity (Se), specificity (Sp), 
positive  predictive  value  (PPV),  negative  predictive  value  (NPV)  and  the  area  under  the  receiving 
operating characteristics curve (AUROC). Results: We found that both markers are able to recognize the 
presence  of  NAFLD.  These  are  the  values  obtained  for  SteatoTest  (controls:  0.176±0.0079,  NAFLD: 
0.744±0.166, p<0.001) and for FLI (controls: 80.29±10.53, NAFLD: 91.1±1.89, p<0.001). The AUROC 
for the diagnosis of steatosis was 0.811 for SteatoTest (Se: 90.32%, Sp: 67.74%, PPV: 77.8%, NPV: 
84.8%)  and  0.808  for  FLI  (Se:  98.33%,  Sp:  54.55%,  PPV:  94.7%,  NPV:  79.7%).  We  also  found 
SteatoTest  and  FLI  useful  for  the  discrimination  between  insignificant  (S0  and  S1)  and  significant 
steatosis (S2 and S3) (p<0.001). Conclusion: SteatoTest and FLI are accurate and easy to use markers 
for  the  diagnosis  of  steatosis  and  they  allowed  differentiation  between  mild/moderate  and  severe 
steatosis. 
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Rezumat. Obiectiv: Scopul studiului de faţă a fost de stabilirea a performanţei diagnostice, pentru doi 
markeri biologic neinvazivi - fatty liver index (FLI) şi SteatoTest. Material şi metodă: Au fost studiaţi 
prospectiv 77 de pacienţi diagnosticaţi cu ficat gras nealcoolic (FGNA) prin biopsie hepatică şi comparaţi 
cu un lot martor de 18 subiecţi sănătoşi. Pacienţii au fost clasificaţi în funcție de gradul histologic de 
steatoză. Au fost utilizate două metode biologice neinvazive FLI si SteatoTest. Valoarea diagnostică a 
fiecărei metode a fost determinată prin sensibilitate (Se), specificitate (Sp), valoare predictivă pozitivă 
(VPP),  valoare  predictivă  negativă  (VPN)  şi  aria  de  sub  curbă  (AUROC).  Rezultate:  Valorile  obţinute 
pentru  ambii  parametrii  studiaţi  au  permis  recunoaşterea  prezenţei  FGNA.  Valorile  obţinute  pentru 
SteatoTest au fost următoarele: lot control (0,176±0,0079), FGNA (0,744±0,166), p<0,001, iar pentru 
FLI: lot control (80,29±10,53), FGNA (91,1±1,89), p<0,001. Valoarea curbei AUROC pentru diagnosticul 
de steatoză a fost de 0,811 pentru SteatoTest (Se: 90,32%, Sp: 67,74%, PPV: 77,8%, NPV: 84,8%) si 
0,808 pentru FLI (Se: 98,33%, Sp: 54,55%, PPV: 94,7%, NPV: 79,7%). S-a obţinut de asemenea, cu 
ajutorul  celor  doi  parametrii  o  bună  departajare  între  steatoza  nesemnificativă  (S0  şi  S1)  şi  cea 
semnificativă (S2 şi S3) (p<0,001). Concluzie: SteatoTest-ul şi indicele FLI au o valoare diagnostică bună 
pentru diagnosticul steatozei şi permit diferenţierea între steatoza uşoară/moderată şi cea severă. 
Cuvinte cheie: ficat gras nealcoolic, SteatoTest, markeri biologici neinvazivi, steatoză. 
 
 
Introduction.  Non-alcoholic  fatty  liver  disease  (NAFLD)  is  a  clinico-histopathological 
entity  with  histological  features  that  resemble  alcohol-induced  liver  injury,  but  by 
definition, it occurs in patients with no history of alcohol consumption. It encompasses a 
histological  spectrum  that  ranges  from  fat  accumulation  in  hepatocytes  without 
concomitant inflammation or fibrosis (simple hepatic steatosis) to hepatic steatosis with a 
necroinflammatory component (steatohepatitis). The latter condition, referred to as non-
alcoholic  steatohepatitis  (NASH),  may  progress  to  cirrhosis  in  up  to  20%  of  patients 
(Matteoni et al 1999; Pais et al 2011; Vernon et al 2011). NASH is now recognized to be 
a leading cause of cryptogenic cirrhosis. 
NAFLD is emerging as the most common chronic liver condition in the Western 
world, affecting 20-40% of the general population (Falck-Ytter et al 2001; Clark et al 90 
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2003;  Adams  et  al  2005;  Sheth  &  Chopra  2008;  De  Lusong  et  al  2008).  The  true 
prevalence of NAFLD and its different stages is unknown. In a hospital-based study that 
took place in Romania and it encompassed 3005 patients, we found an overall prevalence 
of NAFLD of 20% (Radu et al 2008).  Obesity and its complications, especially type 2 
diabetes and hypertriglyceridemia, are likely to be the main causes of the current NAFLD 
epidemic (Adams et al 2010).  
Liver  steatosis  is  often  found  in  association  with  common  cardiometabolic 
disorders, conditions that may all occur in a shared context of abdominal obesity and 
dyslipidemia (Perseghin 2011). 
Liver biopsy is considered to be the golden standard for diagnosis of NAFLD, but 
the technique is invasive and usually painful. Consequently, serum liver function tests 
have been used as indirect or surrogate tests to diagnose NAFLD (Poynard et al 2005; 
Bedogni et al 2006). 
The fatty liver index (FLI) is an algorithm for the prediction of steatosis based on 
4 anthropometrical and biochemical factors. 
SteatoTest
TM (Biopredictive, Paris, France) is a simple blood test, combining 10 
blood components, developed in order to provide an estimate of quantitative steatosis in 
NAFLD (Poynard et al 2005).  
The aim of this study was to establish the diagnostic performance of these two 
biological  markers  (FLI  and  SteatoTest)  for  the  identification  of  hepatic  steatosis  and 
assessing its degree. 
 
Material  and  Methods.  Seventy  seven  patients  with  biopsy-proven  NAFLD  were 
prospectively studied and compared with 18 healthy subjects that did not presented any 
metabolic or hepatic disease that could induce hepatic steatosis and that had a normal 
liver on US examination. 
  The exclusion criteria were: other etiologies of chronic liver disease: B or C viral 
chronic  hepatitis,  autoimmune  hepatitis,  Wilson’s  disease,  history  of  hepatotoxic  or 
steatosis-inducing drug use, alcohol consumption (>20 g day
-1 for women, >30 g day
-1 
for men) and personal history of diabetes mellitus. 
  Each studied patient was submitted to an abdominal ultrasound exam using a GE 
Logiq 7 device with a 5.5 MHz convex probe, the day prior to the liver biopsy. 
  Liver  biopsy  was  the  main  reference  factor  used  to  assess  the  contribution  of 
biochemical markers in the diagnosis of steatosis. 
  The degree of hepatic steatosis in NAFLD patients was assessed according to the 
Kleiner criteria: grade 0: fat droplets <5% hepatocytes (S0); grade 1: fat droplets in 5-
33% hepatocytes (S1); grade 2: fat droplets in 33-66% hepatocytes (S2) and grade 3: 
fat droplets in > 66% hepatocytes (S3) (Kleiner et al 2005). 
  FLI is a composite index which combines 4 parameters: body mass index (BMI), 
waist circumference (WC), triglycerides and gamma-glutamyl transpeptidase (GGT) in a 
mathematical algorithm, developed to detect the presence of steatosis. 
 
FLI = [e 0.953*loge (triglycerides) + 0.139*BMI + 0.718*loge (GGT) + 
0.053*WC - 15.745] / [1 + e 0.953*loge (triglycerides) + 0.139*BMI + 
0.718*loge (GGT) + 0.053*WC- 15.745] * 100 
 
The score varies from 0 and 100. A FLI score < 30 rules out NAFLD, while a FLI score ≥ 
60 indicates fatty liver disease (Bedogni et al 2005). 
  SteatoTest
TM  combines  10  blood  components:  alpha2  macroglobulin  (g  L
-1), 
haptoglobin  (g  L
-1),  apolipoprotein  A  (g  L
-1),  total  bilirubin  (µmol  L
-1),  GGT  (IU  L
-1), 
ALT(IU L
-1), AST(IU  L
-1), total cholesterol (mmol L
-1), triglycerides (mmol L
-1), fasting 
glucose  (mmol  L
-1)  with  age,  gender  and  BMI.    ST  uses  numerical  values  that  are 
inserted in the Biopredictive website. ST scores range from 0 to 1.00 with higher scores 
indicating a greater probability of significant lesions.  
  SteatoTest
TM  is  part  of  the  more  complex  FibroMax
TM
  test;  all  these  tests  are 
patented algorithms (Biopredictive, France) and are provided with instructions for use, 
securing their interpretation (Poynard et al 2005; Munteanu et al 2008). 
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Statistical  analysis.  The  quantitative  data  were  expressed  as  mean  ±  SD  and 
significance  was  established  by  Student’s  t  test  and  ANOVA  (one-way  analysis  of 
variance, with post hoc test Tukey). The diagnostic value for each method was assessed 
using sensitivity (Se), specificity (Sp), positive predictive value (PPV), negative predictive 
value (NPV) and the area under the receiving operating characteristics curve (AUROC). 
The statistical analysis was performed using the MedCalc® 9.3.9.0. software. 
The study was performed in full accordance with the Declaration of Human Rights 
(Helsinki,  1975)  and  with  its  further  revisions.  A  complete,  comprehensive  and  clear 
informed  consent  was  provided  for  patients.  The  study  protocol  excluded  vulnerable 
persons, prisoners, mentally impaired persons, severely injured patients, with no legal 
representatives to sign the consent in their place.  
  The study was approved by the local ethical committee of the Clinical Emergency 
Hospital “Prof. Dr. Octavian Fodor” Cluj-Napoca. All patients gave prior informed consent 
for being included in the study. 
 
Results. The characteristics of the control group and patients are shown in Table 1. 
 
Table 1 
Clinical and biological features of the patients 
 
Variables  Controls (n=18)  NAFLD (n=77) 
  Mean ± DS  Mean ± DS 
Age (years)  38.66±12.67  45.62±10.95 
BMI (kg m
-2)  21.81±2.25  30.09±4.46 
Waist circumference (cm)  73.12±5.92  103.5±14.81 
GGT (U L
-1)  24.77±7.96  98.02±101.63 
Triglycerides (mg dL
-1)  104.94±40.86  237.17±158.46 
SteatoTest  0.176±0.079  0.744±0.166 
FLI  80.29±10.53  91.1±1.89 
Male (number and percentage)  4 (6.56%)  57(93.44%) 
   
A significant difference between the mean values was found for each parameter both in 
controls and in NAFLD patients (Fig. 1). 
 
 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Values of SteatoTest (1a) and FLI (1b) depending on the presence or absence 
of steatosis (Mean ± SD). 
   
 
We  also  obtained  a  good  discriminating  value  between  insignificant  (grade  0-1)  and 
significant (grade 2-3) steatosis (see Figure 2). 
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Figure 2. Values of SteatoTest (2a) and FLI (2b) for significant/insignificant steatosis 
(Mean ± SD). 
 
 
Median ± SD of SteatoTest and FLI for different grades of steatosis showed a significant 
difference  between  steatosis  grade  0  and  other  grades  of  steatosis  (Fig.  3,  Table  2). 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Values of SteatoTest (3a) and FLI (3b) depending on steatosis grade 
 (Mean ± SD). 
 
Table 2 
Mean difference of SteatoTest and FLI according to steatosis grades 
 
Parameter  Mean difference  p 
SteatoTest     
S0-1  6.18  0.001 
S0-2  6.41  0.002 
S0-3  5.76  0.015 
FLI     
S0-1  0.31  0.000 
S0-2  0.33  0.000 
S0-3  0.32  0.000 
   
Further on, we tried to compare the AUROCs for these two parameters according to the 
grade of steatosis (Figs 4-6). 93 
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Figure 4. AUROC for attenuation ST and FLI for the diagnosis of hepatic steatosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. AUROC for ST and FLI for mild steatosis compared with  
moderate and severe steatosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. AUROC for ST and FLI for mild/moderate steatosis compared  
with severe steatosis. 
 
The diagnostic value of the cut-off values of these two parameters is shown in Table 3.  94 
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Table 3 
Diagnostic value of SteatoTest and FLI in hepatic steatosis 
 
Parameter  SteatoTest  FLI 
Cut-off value  ≤ 0.5  86.90 
AUROC  0.811  0.808 
95% CI  0.717-0.885  0.713-0.882 
Se%  90.32  98.33 
Sp%  67.74  54.55 
PPV%  77.8  94.7 
NPV%  84.8  79.7 
p  0.0001  0.0001 
  
Discussion  and  Conclusions.  The  increasing  prevalence  of  NAFLD  in  the  general 
population has compelled the research community to identify accessible, cheap, fast and 
reproducible means for the diagnosis and also for the screening of this condition. 
  The  main  screening  method  is  still  classical  ultrasonography,  a  widely-spread, 
accessible,  fast  method  with  good  diagnostic  performance:  sensibility  67%,  specificity 
77% and positive predictive value 67% (Graif et al 2000). 
  However, classical ultrasonography can only provide an approximate assessment 
of the degree of fatty liver infiltration.  
  Liver  biopsy  has  long  remained  the  "gold  standard",  other  investigations  are 
referred to for the diagnosis of this condition, despite its invasiveness, morbidity and 
mortality risks, high cost and sampling errors. 
  Predicting the degree of fatty infiltration of hepatocytes is of high importance for 
the  evolution  of  NAFLD,  due  to  the  physiopathologic  link  between  fatty  infiltration 
(lipotoxicity)  and  evolution  towards  fibrosis,  based  on  insulin  resistance  (IR)  as  the 
initiating factor. The progression of IR is the "first hit" and induces simple liver steatosis; 
the  "second  hit"  factors  (reactive  oxygen  species,  mitochondrial  dysfunction, 
endotoxemia) lead  to  the  establishment  of  NASH,  fibrogenetic  response  and  potential 
evolution towards cirrhosis (Day 2002; Browning & Horton 2004). 
  Steatosis  can  be  assessed  both  through  pathologic  examination  (with  all  its 
possible drawbacks) and through the use of non-invasive biological tests. 
  In order to avoid the pathologic examination, a computerized system allowing a 
quantitative estimation of steatosis regardless of its origin (NAFLD, viral chronic hepatitis, 
alcoholic liver disease) was developed. The grade of steatosis is expressed in numbers 
between 0-1 and it combines 10 biological parameters: alfa2 macroglobulin, haptoglobin, 
apolipoprotein A1, bilirubin, GGT, ALT, AST, fasting glucose, triglycerides and cholesterol 
with age, gender and BMI. 
  Using the system patented by Biopredictive.com, a satisfactory estimation of the 
degree of steatosis can be obtained (Table 4). 
Table 4 
Conversion from SteatoTest to steatosis grade 
 
SteatoTest  Steatosis percentage 
0.69-1.00  S:>32% 
0.57-0.68  S:6-32% 
0.38-0.56  S:1-5% 
0.00-0.37  S:0% 
 
The  results  obtained  in  this  study  indicated  a  significant  low  score  of  SteatoTest  for 
controls. The SteatoTest AUROC for the prediction of steatosis had a good value (0,811) 
with a cut-off value (0.5) of high sensitivity, specificity, PPV and NPV. Our data showed a 
better value for AUROC for the detection of steatosis and a higher cut-off value compared 
to data found by the original authors (AUROC 0.800, cut-off value 0.38) (Poynard et al 
2005; Munteanu et al 2008). 95 
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  We also found a good SteatoTest value for the discrimination between insignificant 
(S0 and S1) and significant steatosis (S2 and S3). The AUROC value in this case was 
0.707. 
  In the present study we were not able to differentiate between grade 1, 2 and 3 of 
steatosis by means of ST and the AUROC for discrimination between mild/moderate and 
severe steatosis only reached 0.612.  
  The  fatty  liver  index,  calculated  with  the  above-mentioned  formula,  has  been 
proposed in the published literature for the diagnosis of steatosis; the authors proposed a 
≥ 60 value for the prediction of NAFLD (Bedogni et al 2006). 
  The present study group yielded significantly higher values for NAFLD patients and 
for discrimination between grade 0 and grade 1, 2 and 3. The cut-off value obtained in 
our study was 89.6-fold higher than the previously published one (≥ 60). 
  The  index  had  a  good  discriminating  value,  however,  for  the  differentiation 
between insignificant (S0-1) and significant (S2-3) steatosis – AUROC 0.664. Recently, 
the same authors, based on this index, developed another one: the lipid accumulation 
product (LAP) cardiometabolic disorders (Bedogni et al 2010). 
  A  limitation  of  the  study  is  the  relatively  small  number  of  patients  included.  
However, it is important to stress-out that all these patients were biopsied.  
  This study is important because externally validates the two noninvasive scores in 
patients with biopsy proved NAFLD.  
  In  conclusion,  our  findings  suggest  that  the  use  of  non-invasive  methods  for 
diagnosis of NAFLD is adequate and accurate. SteatoTest and FLI are precise and easy to 
use for diagnosis of steatosis and for differentiation between mild/moderate and severe 
steatosis.  FLI  contains  routine  lab  tests,  is  cheaper  and  has  similar  efficiency  to 
SteatoTest  for  detection  of  steatosis  and  its  degree.  The  complementary  use  of  two 
biological methods could improve the diagnostic accuracy.  
  In practice, the two indices could be used for the detection of steatosis patients in 
order to offer nutrition and lifestyle counselling, as well as for the detection of severe 
steatosis patients requiring medical supervision and therapy. 
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